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Abstract
Background: Approximately half of new invasive breast cancer cases diagnosed each year in the United States
occur among women aged 65 years and older. The increasing life expectancy coupled with the attendant rise in
breast cancer incidence and elimination of out-of-pocket expenses for screening mammography as a result of the
Affordable Care Act could lead to higher utilization rates of screening mammography. Although research indicates
that life expectancy should be a strong consideration when making screening decisions among older women, the
extent to which screening mammography utilization is tailored to comorbidity and life expectancy is not well
established.
Methods/design: To identify relevant studies, a systematic search of the literature will be conducted using PubMed
and EMBASE between January 1, 1991, and March 1, 2016. Additional studies will be found through citation review
or by contacting experts in the field. The inclusion criteria will be any study design comprised of women aged 65
and older, assessing women’s comorbidity, functional impairments, and/or health status, and reporting outcome
measures that addressed mammography utilization within the last 1–5 years. For each study, two authors will
independently abstract data regarding study eligibility and outcomes to determine relevance. Quantitative results
will be extracted from text and tables, choosing preferably those adjusted for important confounders.
Discussion: The review will provide evidence on the impact of comorbidity, functional limitations, and health
status on screening mammography utilization in older women and inform decision aids in this area.
Systematic review registration: PROSPERO CRD42016032661
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Background
About half of new invasive breast cancer cases diagnosed
each year in the United States (US) occur among women
aged 65 years and older [1, 2]. The median age of breast
cancer diagnosis is 61 years of age, with a median age at
death of 68 years [3]. According to the US Preventive
Services Task Force (USPSTF), insufficient evidence is
available to recommend screening in women over age
74 years [4]. In 2015, the American Cancer Society
(ACS) recommended continued screening for women
aged 70 years and older on a routine basis as long as
they are in good health [2, 5].
The incidence of breast cancer, the second most common
cause of cancer death in US women, increases with age [6].
Recently, approximately 65–70 % of women aged ≥70 years
continuously reported undergoing screening mammog-
raphy from 2007 to 2012 in the Behavioral Risk Factor
Surveillance System [7]. Consistent with this, data from the
National Health Interview Survey [8] show considerable
screening utilization among women in poor health. Thus,
many older women undergoing screening mammography
experience the consequences of screening without knowing
if there is a benefit from screening. Given the long natural
history of breast cancer in older women and increased
competing causes of death, there comes a time when older
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women may not live long enough to benefit from screening
mammography [9–11]. A recent meta-analysis concluded
that breast cancer screening is most appropriate in women
with a life expectancy of at least 10 years [2, 12, 13].
To date, there has been no published synthesis of
evidence on screening mammography utilization in older
women in relation to comorbidity or functional limitations.
Comorbidity is generally evaluated based on the number
and severity of individual conditions. Two notable comor-
bidity indices include the Charlson Comorbidity Index,
which estimates the risk of mortality from comorbid disease
by summing and weighting each condition, and the
Elixhauser Index, which assesses patient comorbidity based
on ICD-9-CM and ICD-10 codes found in administrative
data [14–16]. Functional limitations are generally examined
based on activities of daily living (ADLs), which are routine
activities that individuals do every day without needing
assistance, including eating, bathing, dressing, toileting,
walking, and continence [17]. Functioning can also be
ascertained using instrumental activities of daily living
(IADLs), defined as complex skills necessary to live inde-
pendently, such as managing finances, preparing meals,
and managing medications and basic home maintenance
[18]. Scales include ADLs or IADLs or a combination of
the two to derive a common score.
Objectives
In this review, we will synthesize the current evidence
on screening mammography utilization in older US
women as a function of comorbid conditions, functional
limitations, and perceived health status. To address this
clinical and policy conundrum, it is important to deter-
mine the extent to which life expectancy affects screen-
ing mammography utilization. We hypothesize that
screening mammography utilization may vary according
to advancing age and life expectancy [19, 20].
Methods
We consulted the Preferred Reporting Items for
Systematic Review and Meta-Analysis Protocols
(PRISMA-P) guidelines while preparing this protocol
and included them as Additional file 1 [21].
Eligibility criteria
The broad inclusion criteria for this review allow for any
study design published in English, including decision
analyses, that (i) include women aged 65 years and older
in the US, (ii) assess women’s comorbidity (either as a
specific condition or a summary score) and/or functional
impairments and/or health status, and (iii) report an
outcome measure that addresses recent screening
mammography utilization. We plan to include any
randomized clinical trials and cohort, case–control,
quasi-experimental, and cross-sectional studies that
meet the above inclusion criteria. Case reports will be
excluded. Most, if not all, of the target population are
Medicare beneficiaries, with screening mammography
covered based on policy changes implemented in 1991
[22]. Women in this age range are near the upper limit
of the USPSTF primary screening mammography guide-
lines (age 74 years) and include age groups where data
are currently inconclusive to provide screening recom-
mendations [9]. To account for the Medicare policy
effect, we will exclude studies evaluating screening
utilization prior to 1991 [22]. Studies must either have
complete populations aged 65 years and older or specific
subgroups aged 65 years or older to be included in the
review.
Information sources and search strategy
The following electronic health databases will be
searched: MEDLINE (using the PubMed interface),
Excerpta Medica Database (EMBASE), Cumulative Index
to Nursing and Allied Health Literature (CINAHL), and
PsycINFO. A systematic search of the literature will be
conducted between January 1, 1991, and March 1, 2016,
to identify all relevant studies in English. Additional
studies will be found by searching editorials, letters,
overview-type articles, and citations of review articles or
by contacting experts in the field regarding any unpub-
lished articles that might be suitable for inclusion.
A search strategy to identify relevant studies will be
developed in collaboration with a librarian. We will
derive initial terms from Medical Subject Headings
(MeSH) of key articles and from other relevant reviews.
We will use “breast neoplasms” combined with permuta-
tions, variations, and abbreviations of the relevant MeSH
keywords and non-MeSH key terms for screening
mammography, age and comorbidity, functional limita-
tions, and health status. Comorbidity terms will include
Charlson and Elixhauser conditions and any other study
comorbidity. An example of a search used for this review
is included in the “Search strategy” section of the
Appendix.
Outcome of interest
The outcome is the screening mammography utilization
in women, defined as screening mammography that
occurred within the last 1–5 years. We anticipate that
studies will measure screening mammography utilization
within the previous 1–5 years and want to ensure that
our review will exclude studies that simply measure ever
having received screening mammography, since it does
not adequately represent recent utilization.
Data management and study selection process
All articles from our MEDLINE and EMBASE searches will
be combined, and duplicates will be removed. As a primary
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screening, titles and abstracts will be reviewed against the
eligibility criteria by two members of the review team (JD
and DB) in duplicate, who both have expertise in cancer
epidemiology and screening. When an article passes
primary screening for either member of the review team,
the full-text version of the study will be obtained and
imported into Mendeley Web (bibliographic database) for
easy access among review team members. Reports of the
same study will be grouped together for easier data extrac-
tion. Using a pre-determined database, we will assess eligi-
bility of each study by reading the full text. The form will
specify all of the eligibility criteria and consist of a table
with the total list of full-text studies retrieved for our
records. Along with these criteria, reviewers will assess the
quality of the studies on the same form.
Comments will be included for excluded studies to
explain the reasoning behind exclusion. The final list
of studies to be included in the review will be added
to a database for further data extraction. A PRISMA
flowchart will be completed to summarize the entire
selection process.
Data extraction
A data extraction form will be used to collect all of the
relevant information from the selected studies. The form
will include information about study characteristics, such
as the type of study, number of participants, length of
follow-up, outcome, and quality assessment. Exposures
logged in this form will separately include comorbidity
scales or specific diseases considered, functional limitation
scales used, and measures of health status. The primary
outcome is screening mammography utilization, defined as
screening mammography that occurred within the last 1–
5 years; odds ratios and the corresponding 95 % confidence
intervals will serve as our effect estimates, with some
studies also showing proportions of utilization. Summary
measures from study participants such as measures of
socioeconomic status, including education and income,
health insurance, and number of physician visits will be
extracted. One team member (JD) will extract the data
from all studies. One other reviewer will independently
assess the data extraction of the other team member for
quality assurance. Any discrepancies will be discussed and
resolved by the review team.
Quality assessment
The team member responsible for data extraction (JD)
will also conduct the quality assessment, which will be
reviewed by a second team member (DB). As part of
the data collection process, we will use the Newcastle-
Ottawa Scale to measure the methodological quality of
the selected observational studies [23]. Additionally,
the Cochrane Collaboration Risk of Bias tool will be
used to assess the quality of randomized controlled
trials [24]. These scales will provide a summary of the




We will conduct a narrative synthesis to describe the
findings of included studies, explore associations of interest,
and examine the quality of the studies and robustness of
the systematic review. Study characteristics, including effect
estimates and main findings, will be summarized compre-
hensively. We will tabulate the full Newcastle-Ottawa and
Cochrane risk of bias findings of individual studies for
descriptive purposes (see Additional file 2).
Quantitative synthesis
Results from each study will be compiled in summary
tables for descriptive comparisons of study findings (see
Additional file 3). We will evaluate three exposures:
comorbidity, functional limitations, and health status.
For each exposure, we will aggregate study findings to
perform meta-analyses assessing the overall magnitude
of the association with recent mammography screening
utilization. We acknowledge that there are variations in
the strategies for measuring each of our exposures,
which will require us to stratify our findings to better
account for study heterogeneity.
For the analysis of the association between comor-
bidity and screening mammography utilization, we will
separate studies that measure specific conditions from
those evaluating comorbidity using a summary score.
Reviewing both individual conditions and comorbidity
indices will enable a comprehensive characterization
of the most debilitating conditions that could affect
screening mammography utilization. Since these are
the primary methods of comorbidity measurement,
stratified analyses will account for potential sources of
heterogeneity.
When analyzing the association between functional
limitations and screening mammography utilization, we
will group studies that only use ADLs versus IADLs ver-
sus both ADLs and IADLs. Finally, for studies analyzing
the association between health status and screening
mammography utilization, we will separate studies that
use a Likert scale health status measure from those using
a prognostic index. Within studies using a prognostic
index, we will perform subgroup analyses to compare
studies that do and do not incorporate ADL or IADL
measurements.
The primary outcome in our meta-analysis will be pooled
odds ratios for screening utilization with corresponding
95 % confidence intervals. In our analyses, we will assess
heterogeneity of studies to determine how structurally
different studies are from each other. We will measure
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study heterogeneity using I2 results and Cochran’s Q from
the meta-analysis groupings. If there is no significant
heterogeneity within our meta-analysis groupings based on
I2 results and Cochran’s Q, we will use the pooled results
over the unpooled findings. While we anticipate that our
studies have similar sample populations with similar condi-
tions, we will use random-effects modeling to analyze study
outcomes because it is a more conservative method to
account for inherent variations between our studies under
the assumption that the effects being estimated in included
studies that are not identical.
Meta-regression controlling for study type, functional
limitation, and comorbidity will be used to identify
causes of heterogeneity. Our response variable will be
the odds ratio of mammography utilization within the
last 1–5 years. Along with study type and exposure
differences (measures of functional limitation and
comorbidity), we will also consider the study year and
the minimum age of the study participants as potential
covariates. We will account for potential residual hetero-
geneity and extra variability in our models by using
random-effects modeling of our meta-regression.
We will also perform sensitivity analyses to examine
potential publication bias including funnel plots, Begg’s test,
Egger’s test, trim and fill, and jackknife analyses and report
these findings in addition to the primary study findings and
subgroup analyses [25]. Moreover, given the differences
between the designs that could lead to different findings,
we plan to perform a sensitivity analysis that separates
randomized clinical trial from observational study findings.
The meta-analysis results will also be graphically displayed
using forest plots [25]. All analyses will be performed using
STATA 13 (Stata, College Station, TX, USA).
Role of the study sponsor
The work represents collaboration between the authors,
who represent a group of academic researchers at the
University of California, San Francisco. All authors
participated in the development of the study design,
manuscript preparation, and the decision to submit the
protocol for publication. All authors will participate in
the data collection and analysis and will be responsible
for data completeness and accuracy. The authors intend
to publish the results for publication.
Discussion
Because of heterogeneity in comorbidity, functional
status, and life expectancy among older women, there is
an urgent need for a more individualized approach to
screening mammography in the elderly [19, 26–28]. The
continuing controversy over screening mammography in
older women indicates a need for evidence to guide
informed choices [29]. Specifically, the consequences of
screening older women have not been well described,
especially in relation to life expectancy. Randomized
trials of screening mammography cannot provide the
evidence because the trials have excluded women older
than age 74 and those with significant comorbidity [27].
This proposal will move the field forward by evaluating
screening mammography utilization in older women
across the levels of advancing age, comorbid illness, and
functional status.
To our knowledge, this review will be the first to
illuminate the impact of life expectancy on screening
mammography uptake in older women. This evidence
synthesis is particularly critical in women ages 65 years
and older, a population that has both a higher incidence
of breast cancer and also an increased risk of death due
to competing causes. Generating direct and previously
unavailable evidence will facilitate informed decisions
regarding breast cancer screening policy for older
women.
A related systematic review conducted by our group has
examined the harms and benefits of breast cancer screening
in older women in relation to comorbidity [19]. We
extend this prior research by evaluating the role of
comorbidity, functional status, and life expectancy in
screening utilization. Moreover, Myers et al. recently
reported that evidence of a relationship between
screening and life expectancy, or quality-adjusted life
expectancy, was lacking [30].
As life expectancy increases and screening mammog-
raphy becomes more widely available, it is important to
develop more individualized screening mammography
approaches or life-expectancy-based screening [26]. For
example, as of 2013, the Affordable Care Act requires
Medicare to cover annual screening mammography at
no cost to women starting at age 45 years with no upper
age limit [31], which may lead to an increase in the rates
of potentially inappropriate screening. Our proposed
review will provide much needed evidence that will
inform breast cancer screening policy and clinical
decision aids.
Reporting and dissemination of findings
We plan to report this review in accordance with the
PRISMA guidelines [32] and to publish the findings in a
peer-reviewed journal. We also intend to present these





Search for Mammography Screening +Aged +Comorbidity
(((("Breast Neoplasms"[Mesh]) AND (("Mammogra-
phy"[Mesh]) OR "Mass Screening"[Mesh]))) AND
((("Aged"[Mesh]) OR ("Aged, 80 and over"[Mesh])) OR
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"Frail Elderly"[Mesh])) AND ((((((((((((((("Cardiovascu-
lar Diseases"[Mesh]) OR "Cognition Disorders"[Mesh])
OR "Comorbidity"[Mesh]) OR "Depression"[Mesh]) OR
"Diabetes Mellitus"[Mesh]) OR "Disabled Persons"[-
Mesh]) OR "Hypertension"[Mesh]) OR "Kidney Disea-
ses"[Mesh]) OR "Myocardial Infarction"[Mesh]) OR
"Mental Disorders"[Mesh]) OR "Heart Diseases"[Mesh])
OR "Stroke"[Mesh]) OR "Intellectual Disability"[Mesh]))
OR "Morbidity"[Mesh])
Additional files
Additional file 1: Table S1. PRISMA-P (Preferred Reporting Items for
Systematic review and Meta-Analysis Protocols) checklist: recommended
items to address in a systematic review protocol. (DOC 53 kb)
Additional file 2: Table S2. Critical evaluation of the quality and
limitations of the studies evaluating benefits and harms of screening
mammography according to comorbidity. (DOC 42 kb)
Additional file 3: Table S3. Summary of findings from studies that
evaluated the effect of summary measures of comorbidity burden on
screening utilization. (DOC 40 kb)
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